Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis

NCT07001800 is registered in ClinicalTrials.gov with Kardigan, Inc. as lead sponsor.

NCT NCT07001800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07001800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis
Lead sponsor
Kardigan, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 27, 2025
Completion date
September 30, 2030
Enrollment
1,276 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

moderate aortic valve stenosis